These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1471423)

  • 1. Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity.
    Azuma I
    Vaccine; 1992; 10(14):1000-6. PubMed ID: 1471423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.
    Koike Y; Yoo YC; Mitobe M; Oka T; Okuma K; Tono-oka S; Azuma I
    Vaccine; 1998 Dec; 16(20):1982-9. PubMed ID: 9796054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of muramyl dipeptide, trehalose dimycolate, and dimethyl dioctadecyl ammonium bromide as adjuvants in Brucella abortus 45/20 vaccines.
    Woodard LF; Toone NM; McLaughlin CA
    Infect Immun; 1980 Nov; 30(2):409-12. PubMed ID: 6777304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brucella abortus vaccines: comparison of protection provided by immunopotentiated 45/20 bacterins and live strain 19 vaccine in guinea pigs.
    Woodard LF; Toone NM; Jasman RL
    Am J Vet Res; 1981 Nov; 42(11):1959-62. PubMed ID: 6802042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of host-defense mechanism with synthetic adjuvants and recombinant cytokines against viral infection in mice.
    Azuma I; Ishihara C; Iida J; Yoo YC; Yoshimatsu K; Arikawa J
    Adv Exp Med Biol; 1992; 319():253-63. PubMed ID: 1329443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of line-10 hepatocellular carcinoma by a less toxic cord factor analogue combined with L18-MDP or synthetic lipid A analogues.
    Ishida H; Saiki I; Saito S; Hasegawa A; Kiso M; Azuma I
    Vaccine; 1988 Oct; 6(5):440-4. PubMed ID: 3195200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection.
    Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y
    Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic vaccines: the role of adjuvants in immune targeting.
    Jiang ZH; Koganty RR
    Curr Med Chem; 2003 Aug; 10(15):1423-39. PubMed ID: 12871139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen.
    Tamura M; Yoo YC; Yoshimatsu K; Yoshida R; Oka T; Ohkuma K; Arikawa J; Azuma I
    Vaccine; 1995 Jan; 13(1):77-82. PubMed ID: 7762283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice.
    Yoo YC; Yoshimatsu K; Hatsuse R; Tamura M; Yoshida R; Tono-oka S; Arikawa J; Azuma I
    Vaccine; 1995 Oct; 13(14):1300-5. PubMed ID: 8585284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (romurtide) in mice and humans.
    Azuma I; Otani T
    Med Res Rev; 1994 Jul; 14(4):401-14. PubMed ID: 8084203
    [No Abstract]   [Full Text] [Related]  

  • 12. Stimulation of non-specific resistance to infection by muroctasin.
    Otani T; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of muramyl dipeptide analogs in combination with trehalose dimycolate against aerogenic influenza virus and Mycobacterium tuberculosis infections in mice.
    Masihi KN; Brehmer W; Lange W; Ribi E; Schwartzman S
    J Biol Response Mod; 1984 Dec; 3(6):663-71. PubMed ID: 6439830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review: inducer of cytokines in vivo: overview of field and romurtide experience.
    Azuma I
    Int J Immunopharmacol; 1992 Apr; 14(3):487-96. PubMed ID: 1618600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental and clinical studies on the effects of synthetic muramyldipeptide derivatives on viral and opportunistic infections.
    Yamamura Y; Ishihara C; Hamada N; Yamamoto K; Azuma I
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):11-4. PubMed ID: 3010013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic immunomodulators and synthetic vaccines.
    Leclerc C; Vogel FR
    Crit Rev Ther Drug Carrier Syst; 1986; 2(4):353-406. PubMed ID: 3103928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic properties of soluble antigens or whole cells of Brucella abortus strain 45/20 associated with immunoadjuvants. II. Whole cells.
    Woodard LF; Toone NM; McLaughlin CA
    Can J Comp Med; 1980 Oct; 44(4):456-8. PubMed ID: 6778600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus.
    Fukushima A; Yoo YC; Yoshimatsu K; Matsuzawa K; Tamura M; Tono-oka S; Taniguchi K; Urasawa S; Arikawa J; Azuma I
    Vaccine; 1996 Apr; 14(6):485-91. PubMed ID: 8782344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of nonspecific host resistance to infection induced by muramyldipeptides.
    Matsumoto K; Ogawa H; Nagase O; Kusama T; Azuma I
    Microbiol Immunol; 1981; 25(10):1047-58. PubMed ID: 7031443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of Corynebacterium pseudotuberculosis and the effect of adjuvants in mice.
    Brogden KA; Cutlip RC; Lehmkuhl HD
    J Comp Pathol; 1985 Apr; 95(2):167-73. PubMed ID: 3837788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.